Glioblastoma: a method for predicting response to antiangiogenic chemotherapy by using MR perfusion imaging--pilot study.
about
Quantitative Perfusion and Permeability Biomarkers in Brain Cancer from Tomographic CT and MR ImagesCurrent standards and new concepts in MRI and PET response assessment of antiangiogenic therapies in high-grade glioma patientsClinical applications of susceptibility-weighted imaging in detecting and grading intracranial gliomas: a reviewCerebrovascular occlusive disease: quantitative cerebral blood flow using dynamic susceptibility contrast mr imaging correlates with quantitative H2[15O] PETAntiangiogenic therapy of brain tumors: the role of bevacizumab.The role of imaging in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline.Post-treatment imaging changes in primary brain tumors.ASFNR recommendations for clinical performance of MR dynamic susceptibility contrast perfusion imaging of the brain.Multimodality intraoperative MRI for brain tumor surgery.Advances in MRI assessment of gliomas and response to anti-VEGF therapy.Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: analysis of single-agent and combined modality approachesChemoirradiation for glioblastoma multiforme: the national cancer institute experience.Evidence for post-translational processing of vascular endothelial (VE)-cadherin in brain tumors: towards a candidate biomarker.Hypervascular tumor volume estimated by comparison to a large-scale cerebral blood volume radiographic atlas predicts survival in recurrent glioblastoma treated with bevacizumab.Parametric response maps of perfusion MRI may identify recurrent glioblastomas responsive to bevacizumab and irinotecan.Bevacizumab-induced tumor calcifications as a surrogate marker of outcome in patients with glioblastoma.T(1)- and T(2)(*)-dominant extravasation correction in DSC-MRI: part II-predicting patient outcome after a single dose of cediranib in recurrent glioblastoma patients.Physiologic MRI for assessment of response to therapy and prognosis in glioblastoma.Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma.Impact of Software Modeling on the Accuracy of Perfusion MRI in Glioma.Early perfusion changes in patients with recurrent high-grade brain tumor treated with Bevacizumab: preliminary results by a quantitative evaluation.Impact of perfusion map analysis on early survival prediction accuracy in glioma patientsProgressing Bevacizumab-Induced Diffusion Restriction Is Associated with Coagulative Necrosis Surrounded by Viable Tumor and Decreased Overall Survival in Patients with Recurrent Glioblastoma.Misleading early blood volume changes obtained using ferumoxytol-based magnetic resonance imaging perfusion in high grade glial neoplasms treated with bevacizumab.Current and emerging molecular targets in glioma.The evolution of imaging in cancer: current state and future challenges.Therapeutic targeting of VEGF in the treatment of glioblastoma.Treating recurrent glioblastoma: an update.Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance?Amino acid PET and MR perfusion imaging in brain tumours.Posttreatment DSC-MRI is Predictive of Early Treatment Failure in Children with Supratentorial High-Grade Glioma Treated with Erlotinib.Emerging techniques and technologies in brain tumor imagingQuantitative volumetric analysis of conventional MRI response in recurrent glioblastoma treated with bevacizumab.Recurrent high-grade glioma treated with bevacizumab: prognostic value of MGMT methylation, EGFR status and pretreatment MRI in determining response and survival.Cell invasion, motility, and proliferation level estimate (CIMPLE) maps derived from serial diffusion MR images in recurrent glioblastoma treated with bevacizumab.Early Biomarkers from Conventional and Delayed-Contrast MRI to Predict the Response to Bevacizumab in Recurrent High-Grade Gliomas.Early perfusion MRI predicts survival outcome in patients with recurrent glioblastoma treated with bevacizumab and carboplatin.Assessment of Progression-Free-Survival in Glioblastomas by Intratreatment Dynamic Contrast-Enhanced MRI.Combined value of susceptibility-weighted and perfusion-weighted imaging in assessing who grade for brain astrocytomas.Antiangiogenic Effect of Bevacizumab: Application of Arterial Spin-Labeling Perfusion MR Imaging in a Rat Glioblastoma Model.
P2860
Q26743358-60792ACC-CD49-4E6D-9B2C-CF73C3A4D11EQ26853308-EC9B0133-C337-4D0D-AED5-13918EED5575Q26864367-3708F132-B86F-4970-A16A-F134C3D5BC87Q30585042-5BAA6B8F-8843-4D22-958B-0C3661CCCDD3Q30737224-3880ADFF-DA87-4C54-BCF6-A96357DC29A9Q30797166-5D8DC62E-3D26-457C-B0A6-30ED2B0382CDQ30835236-DBAF083C-F6CB-41F4-80BF-86F5BD3D09A9Q30938805-54753839-A10F-4A87-8C8B-4BB803801213Q33718297-B491A281-903D-4196-9A99-8FFBA7F21ED6Q33793253-67CC5797-AB2E-4D0F-9A5F-5411AB2F9086Q34515465-2FDD4E37-D8D5-44B4-B308-70201D2FE9DEQ34935862-378600C2-FF06-419B-8910-D94D67009C1FQ35072480-E12E808B-4DE9-4C46-A3E6-A6B37C23309CQ35093286-B53F7176-090B-4719-980F-8EFCB7EF9440Q35133246-6921B513-0D0C-4EF1-B5F3-EE15B661C260Q35170377-52EE2469-C078-4C14-A14D-A21A0664CF01Q35524040-30A133D3-4CD3-4FC7-BD77-89D4572282B3Q35771783-9C9501FD-0122-43D7-8E74-FD78FCA9ABD1Q35895174-7E3703D5-EAD4-434F-8BB5-9B2C6F0DEEFDQ36378153-D9E13DD7-8050-4478-B98D-3F573558C99FQ36641544-C9FC8761-86B8-4663-93BC-DBE39B065AA6Q37474416-3B4649DE-5983-47B4-894E-417F08FE47D2Q37510450-C7934AC6-166F-4358-A076-D5C6DE0AD841Q37523107-EF948692-9E5E-453B-AFC6-C5CCBD0825F0Q37809861-5AB02216-A636-4A3A-AB93-794682C7A632Q37848518-E7CE26D9-A553-45F3-8EF0-728460A3E1ACQ38033241-32BDB9C5-E4F1-4609-A8A3-313D64EFF620Q38376610-58317A30-1BA1-4168-B7DD-F7C2A5C9D1C5Q38635290-921AE54F-A11A-4AA1-A012-8CF6C505F030Q38691946-9384AA95-9E68-41BA-B494-4EB9D8AB5576Q38734338-A61E53B1-771E-40FF-9A1C-1DFB1195C56FQ41995781-9F4116CE-42E8-4F19-B4C3-9D2A0FA15998Q42704114-EB3B651D-EFE4-4663-9DB7-BD1FA6584A6DQ44362904-F4BC4FAD-603D-43ED-AF3D-97D4660D9C75Q44438842-05636A54-8F3F-45A3-883F-00124BA060E8Q48168860-9F8DAD54-7DA3-487E-B362-60DBED13EAECQ48192001-2F745A28-0B95-467E-BB87-734C87F2961DQ48579677-3343DE9D-427F-481C-A1A3-94722BC40102Q48682004-B8C9D404-5592-429D-8DAE-7CC5E251EADAQ48739694-54E8CADD-13A3-447F-81E1-2BB89907F980
P2860
Glioblastoma: a method for predicting response to antiangiogenic chemotherapy by using MR perfusion imaging--pilot study.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Glioblastoma: a method for pre ...... erfusion imaging--pilot study.
@ast
Glioblastoma: a method for pre ...... erfusion imaging--pilot study.
@en
Glioblastoma: a method for pre ...... erfusion imaging--pilot study.
@nl
type
label
Glioblastoma: a method for pre ...... erfusion imaging--pilot study.
@ast
Glioblastoma: a method for pre ...... erfusion imaging--pilot study.
@en
Glioblastoma: a method for pre ...... erfusion imaging--pilot study.
@nl
prefLabel
Glioblastoma: a method for pre ...... erfusion imaging--pilot study.
@ast
Glioblastoma: a method for pre ...... erfusion imaging--pilot study.
@en
Glioblastoma: a method for pre ...... erfusion imaging--pilot study.
@nl
P2093
P2860
P356
P1433
P1476
Glioblastoma: a method for pre ...... erfusion imaging--pilot study.
@en
P2093
Christopher Getch
James P Chandler
Jeffrey Raizer
Rahul N Sawlani
Robert Levy
Sandra W Horowitz
Sean A Grimm
Timothy J Carroll
Wanyong Shin
P2860
P304
P356
10.1148/RADIOL.10091341
P407
P577
2010-05-01T00:00:00Z